BALAJI TELEFILMS LTD

Balaji Telefilms (BTL) was incorporated as a private limited company and subsequently converted to a public limited company in Feb., 2000. The company is promoted by Ravi Kapoor, Shobha Kapoor and Ekta Kapoor. Headquartered in Mumbai, the promoter family owns 42 per cent of the company`s equity.

Balaji is currently providing content to most of the Hindi satellite channels, Gemini in Telugu and Udaya in Kannada. Its success in the television software market is attributed to its early entry into the market and its local presence at Mumbai, Chennai & Bangalore.

As of March 2006, Balaji Telefilms runs seven soaps on Star Plus, one show on Zee TV and two shows on Sony. The production house also has seven shows for the southern market. Nearly 85 percent of its revenue comes from Hindi programming, 8 percent from Telugu, 5 percent from Kannada and 4 percent from Tamil and Malayalam. BTL content caters to a wide spectrum of audience through its diverse software which includes sitcoms, soaps, game shows, fantasy and adventure, suspense and thriller and children`s programmes in Hindi as well as regional languages.

Stock Looking Good For Coming Days Target 120

Comments

Best Buy For Monday Upper Circuit Expected TCI FINANCE

*Intraday & Short Term News For Monday* *Fii And Dii News* *TCI FINANCE LTD (501242 & NSE) (31)* Incorporated in 1973, TCI Finance Ltd (TCIFL) is a Non-Banking Finance Company (NBFC) registered with the RBI and engaged in the business of Inter-Corporate Deposits, investment in equities of bodies corporate etc. The Company was promoted by Mr. Mahendra Agarwal, who is also the Managing Director and CEO of Gati Ltd, a pioneer in express distribution and supply chain and promoted by TCFIL The Rs.2 paid-up share of Gati Ltd currently trades at Rs.113. TCIFL has one subsidiary - ITAG Business Solutions Ltd engaged in the business of Knowledge Process Outsourcing (KPO) in the domain of Intellectual Property Services. *It is co-promoter of GATI LTD. Company is holding 55,12,455 shares (5.09%) stake in GATI LTD. At CMP value of investments is around Rs.62.3crore. Equity is Rs.12.87crore. Thus value of investment works out to Rs.48.4 per share & market cap of compan

Danlaw Technologies India Ltd: For multi-bagger gains (BSE Code: 532329) (CMP: Rs. 60.75) (FV: Rs.10)

The earnings season so far has been weak and worries over domestic growth continue to weigh on the market sentiment which has led the markets back on the downward path.. A value investor, however, need not worry about the broad markets as value stocks perform better and post good results. One such value-pick is Danlaw Technologies India Ltd. (DTIL). Company background: DTIL is the offshore technology and product development center of its parent company - Danlaw Incorporated, founded by Mr. Raju Dandu and Mr. Lloyd Lawrence in Michigan, USA in 1984. DTIL’s mission is to provide high quality services and products in Automotive Electronics, develop R&D driven Signal Processing technologies for communication and control, configure solutions and provide exceptional Information Technology (IT) services in the areas of education, health, banking and e-governance and provide world-class products and solutions for secured access through biometric access control technologies with intellige

Some Opportunities Are left in Pharma Sector

Torrent Pharmaceuticals reported impressive 75% growth in revenues and profit in the first quarter of FY 2016. The sterling performance was driven by the launch of new product in the US market, which has limited competition at present. The focus is on the therapeutic segments of cardiovascular and CNS. There is presence in gastro-intestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology and pediatric segments as well. The manufacturing plants for formulations and bulk drugs have been approved by authorities of several regulated and semi-regulated markets such as the US, the UK, Brazil, Germany, Australia and South Africa. Capacity will increase almost 100% once the new plant at Dahej in Gujarat becomes operational. The plant will be one of the largest pharmaceuticals manufacturing facilities in the country at a single location. The unit will primarily cater to the key regulated markets of the US and Europe. Approval from regulators such as

Value Research

Search This Blog